Llwytho...
Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
Ticagrelor is the first reversible, direct-acting, potent P2Y(12) receptor antagonist in management of acute coronary syndromes. It is rapidly absorbed and extensively metabolized. AR-C124910XX, the major active metabolite, antagonizes the P2Y(12) receptor at approximately equal potency. The metabol...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Front Pharmacol |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5374142/ https://ncbi.nlm.nih.gov/pubmed/28408884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00176 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|